An eight-week course of treatment with the daily oral drug glecaprevir/pibrentasvir cured chronic hepatitis C virus (HCV) infection in 98% of previously untreated patients with an asymptomatic form of cirrhosis or liver scarring known as compensated cirrhosis.
